Curcumin as a regulator of epigenetic events

Molecular Nutrition and Food Research

Volumn 57, Issue 9, 2013, Pages 1619-1629

  Teiten, Marie Hélène ^a   Dicato, Mario ^a   Diederich, Marc ^b  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

^b Seoul National University   (South Korea)

Author keywords

Cancer; Curcumin; DNA methylation; Histone modifications; MiRNA

Indexed keywords

CURCUMIN; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; MICRORNA;

ANIMAL; DISEASE MODEL; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HISTONE MODIFICATIONS; HUMAN; METABOLISM; NEOPLASM; PROMOTER REGION; REVIEW;

CANCER; CURCUMIN; DNA METHYLATION; HISTONE MODIFICATIONS; MIRNA;

ANIMALS; CURCUMIN; DISEASE MODELS, ANIMAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; MICRORNAS; NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 84883387232     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300201     Document Type: Review

References (118)

1. Jones, P. A., Baylin, S. B., The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
2. Sawan, C., Vaissiere, T., Murr, R., Herceg, Z., Epigenetic drivers and genetic passengers on the road to cancer. Mutat. Res. 2008, 642, 1-13.
3. Szyf, M., DNA methylation and demethylation as targets for anticancer therapy. Biochemistry 2005, 70, 533-549.
4. Egger, G., Liang, G., Aparicio, A., Jones, P. A., Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429, 457-463.
5. Florean, C., Schnekenburger, M., Grandjenette, C., Dicato, M. et al., Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 2011, 3, 581-609.
6. Dawson, M. A., Kouzarides, T., Cancer epigenetics: from mechanism to therapy. Cell 2012, 150, 12-27.
7. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. et al., Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21, 103-107.
8. Davis, C. D., Ross, S. A., Dietary components impact histone modifications and cancer risk. Nutr. Rev. 2007, 65, 88-94.
9. Ehrlich, M., DNA hypomethylation in cancer cells. Epigenomics 2009, 1, 239-259.
10. Kulis, M., Esteller, M., DNA methylation and cancer. Adv. Genet. 2010, 70, 27-56.
11. Mani, S., Herceg, Z., DNA demethylating agents and epigenetic therapy of cancer. Adv. Genet. 2010, 70, 327-340.
12. Kouzarides, T., Chromatin modifications and their function. Cell 2007, 128, 693-705.
13. Sawan, C., Herceg, Z., Histone modifications and cancer. Adv. Genet. 2010, 70, 57-85.
14. Strahl, B. D., Allis, C. D., The language of covalent histone modifications. Nature 2000, 403, 41-45.
15. Bannister, A. J., Kouzarides, T., Regulation of chromatin by histone modifications. Cell. Res. 2011, 21, 381-395.
16. Grunstein, M., Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
17. Steger, D. J., Workman, J. L., Remodeling chromatin structures for transcription: what happens to the histones? Bioessays 1996, 18, 875-884.
18. Zhang, K., Dent, S. Y., Histone modifying enzymes and cancer: going beyond histones. J. Cell Biochem. 2005, 96, 1137-1148.
19. Vandenboom Ii, T. G., Li, Y., Philip, P. A., Sarkar, F. H., MicroRNA and cancer: tiny molecules with major implications. Curr. Genomics 2008, 9, 97-109.
20. Fabbri, M., Calin, G. A., Epigenetics and miRNAs in human cancer. Adv. Genet. 2010, 70, 87-99.
21. Winter, J., Diederichs, S., MicroRNA biogenesis and cancer. Methods Mol. Biol. 2011, 676, 3-22.
22. Hardy, T. M., Tollefsbol, T. O., Epigenetic diet: impact on the epigenome and cancer. Epigenomics 2011, 3, 503-518.
23. Khan, S. I., Aumsuwan, P., Khan, I. A., Walker, L. A. et al., Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem. Res. Toxicol. 2012, 25, 61-73.
24. Mai, A., Altucci, L., Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41, 199-213.
25. Meeran, S. M., Ahmed, A., Tollefsbol, T. O., Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenet. 2010, 1, 101-116.
26. Suzuki, T., Miyata, N., Epigenetic control using natural products and synthetic molecules. Curr. Med. Chem. 2006, 13, 935-958.
27. Vanden Berghe, W., Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol. Res. 2012, 65, 565-576.
28. Paluszczak, J., Krajka-Kuzniak, V., Baer-Dubowska, W., The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett. 2010, 192, 119-125.
29. Ho, E., Beaver, L. M., Williams, D. E., Dashwood, R. H., Dietary factors and epigenetic regulation for prostate cancer prevention. Adv. Nutr. 2011, 2, 497-510.
30. Huang, J., Plass, C., Gerhauser, C., Cancer chemoprevention by targeting the epigenome. Curr. Drug. Targets 2011, 12, 1925-1956.
31. Fu, S., Kurzrock, R., Development of curcumin as an epigenetic agent. Cancer 2010, 116, 4670-4676.
32. Reuter, S., Gupta, S. C., Park, B., Goel, A. et al., Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011, 6, 93-108.
33. Ye, M. X., Li, Y., Yin, H., Zhang, J., Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int. J. Mol. Sci. 2012, 13, 3959-3978.
34. Aggarwal, B. B., Bhatt, I. D., Ichikawa, H., Ahn, K. S. et al., Curcumin: Biological and Medicinal Properties, in Turmeric: The Genus Curcuma CRC Press, New York 2007.
35. Hatcher, H., Planalp, R., Cho, J., Torti, F. M. et al., Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life Sci. 2008, 65, 1631-1652.
36. Teiten, M. H., Eifes, S., Dicato, M., Diederich, M., Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2010, 2, 128-162.
37. Goel, A., Kunnumakkara, A. B., Aggarwal, B. B., Curcumin as "curecumin": from kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787-809.
38. Teiten, M. H., Gaigneaux, A., Chateauvieux, S., Billing, A. M. et al., Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS 2012, 16, 289-300.
39. Balogun, E., Hoque, M., Gong, P., Killeen, E. et al., Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003, 371, 887-895.
40. Sandur, S. K., Pandey, M. K., Sung, B., Ahn, K. S. et al., Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007, 28, 1765-1773.
41. Kelkel, M., Jacob, C., Dicato, M., Diederich, M., Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules 2010, 15, 7035-7074.
42. Menon, V. P., Sudheer, A. R., Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 2007, 595, 105-125.
43. Teiten, M. H., Eifes, S., Reuter, S., Duvoix, A. et al., Gene expression profiling related to anti-inflammatory properties of curcumin in K562 leukemia cells. Ann. N.Y. Acad. Sci. 2009, 1171, 391-398.
44. Reuter, S., Charlet, J., Juncker, T., Teiten, M. H. et al., Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells. Ann. N. Y. Acad. Sci. 2009, 1171, 436-447.
45. Duvoix, A., Blasius, R., Delhalle, S., Schnekenburger, M. et al., Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005, 223, 181-190.
46. Reuter, S., Eifes, S., Dicato, M., Aggarwal, B. B. et al., Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 2008, 76, 1340-1351.
47. Bhandarkar, S. S., Arbiser, J. L., Curcumin as an inhibitor of angiogenesis. Adv. Exp. Med. Biol. 2007, 595, 185-195.
48. Kunnumakkara, A. B., Anand, P., Aggarwal, B. B., Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008, 269, 199-225.
49. Seidel, C., Florean, C., Schnekenburger, M., Dicato, M. et al., Chromatin-modifying agents in anti-cancer therapy. Biochimie 2012, 94, 2264-2279.
50. Das, P. M., Singal, R., DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632-4642.
51. Liu, Z., Xie, Z., Jones, W., Pavlovicz, R. E. et al., Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 2009, 19, 706-709.
52. Parashar, G., Parashar, N. C., Capalash, N., Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line. Mol. Cell Biochem. 2012, 365, 29-35.
53. Abusnina, A., Keravis, T., Yougbare, I., Bronner, C. et al., Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol. Nutr. Food Res. 2011, 55, 1677-1689.
54. Du, L., Xie, Z., Wu, L. C., Chiu, M. et al., Reactivation of RASSF1A in breast cancer cells by curcumin. Nutr. Cancer 2012, 64, 1228-1235.
55. Shu, L., Khor, T. O., Lee, J. H., Boyanapalli, S. S. et al., Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 2011, 13, 606-614.
56. Jha, A. K., Nikbakht, M., Parashar, G., Shrivastava, A. et al., Reversal of hypermethylation and reactivation of the RARbeta2 gene by natural compounds in cervical cancer cell lines. Folia Biol. 2010, 56, 195-200.
57. Khor, T. O., Huang, Y., Wu, T. Y., Shu, L. et al., Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol. 2011, 82, 1073-1078.
58. Wang, Z., Li, M., Lu, S., Zhang, Y. et al., Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol. Ther. 2006, 5, 256-260.
59. Liu, Y. L., Yang, H. P., Gong, L., Tang, C. L. et al., Hypomethylation effects of curcumin, demethoxycurcumin and bisdemethoxycurcumin on WIF-1 promoter in non-small cell lung cancer cell lines. Mol. Med. Report. 2011, 4, 675-679.
60. Saini, S., Arora, S., Majid, S., Shahryari, V. et al., Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. 2011, 4, 1698-1709.
61. Roy, S., Levi, E., Majumdar, A. P., Sarkar, F. H., Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J. Hematol. Oncol. 2012, 5, 58.
62. Rothbart, S. B., Krajewski, K., Nady, N., Tempel, W. et al., Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. Nat. Struct. Mol. Biol. 2012, 19, 1155-1160.
63. Jenkins, Y., Markovtsov, V., Lang, W., Sharma, P. et al., Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol. Biol. Cell 2005, 16, 5621-5629.
64. Folmer, F., Orlikova, B., Schnekenburger, M., Dicato, M. et al., Naturally occuring regulators of histone acetylation/deacetylation. Curr. Nutr. Food. Sci. 2010, 6, 78-99.
65. Seidel, C., Schnekenburger, M., Dicato, M., Diederich, M., Histone deacetylase modulators provided by Mother Nature. Genes Nutr. 2012, 7, 357-367.
66. Delage, B., Dashwood, R. H., Dietary manipulation of histone structure and function. Annu. Rev. Nutr. 2008, 28, 347-366.
67. Manzo, F., Tambaro, F. P., Mai, A., Altucci, L., Histone acetyltransferase inhibitors and preclinical studies. Exp. Opin. Ther. Pat. 2009, 19, 761-774.
68. Balasubramanyam, K., Varier, R. A., Altaf, M., Swaminathan, V. et al., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163-51171.
69. Shankar, S., Srivastava, R. K., Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 2007, 30, 905-918.
70. Marcu, M. G., Jung, Y. J., Lee, S., Chung, E. J. et al., Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2006, 2, 169-174.
71. Kang, S. K., Cha, S. H., Jeon, H. G., Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 2006, 15, 165-174.
72. Yuan, Z., Syed, M. A., Panchal, D., Rogers, D. et al., Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int. J. Biochem. Cell Biol. 2012, 44, 2032-2043.
73. Steelman, L. S., Stadelman, K. M., Chappell, W. H., Horn, S. et al., Akt as a therapeutic target in cancer. Exp. Opin. Ther. Targets 2008, 12, 1139-1165.
74. Chen, Y., Shu, W., Chen, W., Wu, Q. et al., Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin. Pharmacol. Toxicol. 2007, 101, 427-433.
75. Yun, J. M., Jialal, I., Devaraj, S., Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J. Nutr. Biochem. 2011, 22, 450-458.
76. Bora-Tatar, G., Dayangac-Erden, D., Demir, A. S., Dalkara, S. et al., Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg. Med. Chem. 2009, 17, 5219-5228.
77. Liu, H. L., Chen, Y., Cui, G. H., Zhou, J. F., Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol. Sin. 2005, 26, 603-609.
78. Wu, Q., Chen, Y., Li, X., HDAC1 expression and effect of curcumin on proliferation of Raji cells. J. Huazhong Univ. Sci. Technology Med. Sci. 2006, 26, 199-201, 210.
79. Lee, S. J., Krauthauser, C., Maduskuie, V., Fawcett, P. T. et al., Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 2011, 11, 144.
80. Royt, M., Mukherjee, S., Sarkar, R., Biswas, J., Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-kappaB and HDAC in breast cancer. Ther. Deliv. 2011, 2, 1275-1293.
81. Lin, K. T., Wang, Y. W., Chen, C. T., Ho, C. M. et al., HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clin. Cancer Res. 2012, 18, 4691-4701.
82. Kao, H. H., Wu, C. J., Won, S. J., Shin, J. W. et al., Kinase gene expression and subcellular protein expression pattern of protein kinase C isoforms in curcumin-treated human hepatocellular carcinoma Hep 3B cells. Plant Foods Hum. Nutr. 2011, 66, 136-142.
83. Lin, J. K., Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by curcumin. Arch. Pharm. Res. 2004, 27, 683-692.
84. Yan, G., Graham, K., Lanza-Jacoby, S., Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol. Carcinog. 2013, 52, 404-411.
85. Croce, C. M., Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704-714.
86. Karius, T., Schnekenburger, M., Dicato, M., Diederich, M., MicroRNAs in cancer management and their modulation by dietary agents. Biochem. Pharmacol. 2012, 83, 1591-1601.
87. Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T. et al., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999-3004.
88. Negrini, M., Ferracin, M., Sabbioni, S., Croce, C. M., MicroRNAs in human cancer: from research to therapy. J. Cell Sci. 2007, 120, 1833-1840.
89. Li, Y., Kong, D., Wang, Z., Sarkar, F. H., Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 2010, 27, 1027-1041.
90. Neelakandan, K., Babu, P., Nair, S., Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr. Cancer Drug Targets 2012, 12, 716-740.
91. Sun, M., Estrov, Z., Ji, Y., Coombes, K. R. et al., Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 2008, 7, 464-473.
92. Kim, S., Lee, U. J., Kim, M. N., Lee, E. J. et al., MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 2008, 283, 18158-18166.
93. Sreenivasan, S., Thirumalai, K., Danda, R., Krishnakumar, S., Effect of curcumin on miRNA expression in human Y79 retinoblastoma cells. Curr. Eye Res. 2012, 37, 421-428.
94. Yang, J., Cao, Y., Sun, J., Zhang, Y., Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med. Oncol. 2010, 27, 1114-1118.
95. Gao, S. M., Yang, J. J., Chen, C. Q., Chen, J. J. et al., Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. J. Exp. Clin. Cancer Res. 2012, 31, 27.
96. Zhang, J., Du, Y., Wu, C., Ren, X. et al., Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol. Rep. 2010, 24, 1217-1223.
97. Tang, N., Zhang, J., Du, Y., [Curcumin promoted the apoptosis of cisplain-resistant human lung carcinoma cells A549/DDP through down-regulating miR-186*]. Zhongguo Fei. Ai. Za. Zhi. 2010, 13, 301-306.
98. Zhang, J., Zhang, T., Ti, X., Shi, J. et al., Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem. Biophys. Res. Commun. 2010, 399, 1-6.
99. Asangani, I. A., Rasheed, S. A., Nikolova, D. A., Leupold, J. H. et al., MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27, 2128-2136.
100. Selcuklu, S. D., Donoghue, M. T., Spillane, C., miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 2009, 37, 918-925.
101. Mudduluru, G., George-William, J. N., Muppala, S., Asangani, I. A. et al., Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. 2011, 31, 185-197.
102. Ali, S., Ahmad, A., Banerjee, S., Padhye, S. et al., Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70, 3606-3617.
103. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C. et al., The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10, 593-601.
104. Li, Y., VandenBoom 2nd, T. G., Kong, D., Wang, Z. et al., Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712.
105. Bao, B., Ali, S., Kong, D., Sarkar, S. H. et al., Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6, e17850.
106. Ali, S., Ahmad, A., Aboukameel, A., Bao, B. et al., Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett. 2012, 319, 173-181.
107. Subramaniam, D., Ponnurangam, S., Ramamoorthy, P., Standing, D. et al., Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One 2012, 7, e30590.
108. Martin, G. S., The hunting of the Src. Nat. Rev. Mol. Cell Biol. 2001, 2, 467-475.
109. Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W. et al., MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007, 67, 8433-8438.
110. Kim, N. H., Kim, H. S., Kim, N. G., Lee, I. et al., p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal 2011, 4, ra71.
111. Wang, Z., Zhang, Y., Banerjee, S., Li, Y. et al., Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106, 2503-2513.
112. Bao, B., Ali, S., Banerjee, S., Wang, Z. et al., Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012, 72, 335-345.
113. Chainani-Wu, N., Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J. Altern. Complement Med. 2003, 9, 161-168.
114. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M. et al., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, 2895-2900.
115. Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D. et al., Dose escalation of a curcuminoid formulation. BMC Compl. Altern. Med. 2006, 6, 10.
116. Sharma, R. A., Euden, S. A., Platton, S. L., Cooke, D. N. et al., Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10, 6847-6854.
117. Sharma, R. A., McLelland, H. R., Hill, K. A., Ireson, C. R. et al., Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001, 7, 1894-1900.
118. Burgos-Moron, E., Calderon-Montano, J. M., Salvador, J., Robles, A. et al., The dark side of curcumin. Int. J. Cancer. 2010, 126, 1771-1775.